13-03491. Droxicam [Archived]

Nomenclature

CAS number: 90101-16-9
5-Methyl-3-(2-pyridinyl)-2H,5H-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide; E-3128; Dobenam (Angelini); Droxar (Upjohn); Ombolan (Esteve).
C16H11N3O5S; mol wt 357.34.
C 53.78%, H 3.10%, N 11.76%, O 22.39%, S 8.97%.

Description and references

Prodrug of piroxicam. Prepn: J. E. Soler, FR 2528433; idem, US 4563452 (1983, 1986 both to Provesan SA). Spectroscopic structural analysis: J. Frigola, J. Chem. Soc. Perkin Trans. 2 1988, 241. Pharmacology: A. J. Farré et al., Methods Find. Exp. Clin. Pharmacol. 8, 407 (1986). Metabolism and pharmacokinetics in animals: A. Esteve et al., ibid. 423. Inhibition of platelet aggregation: J. Esteve et al., ibid. 9, 209 (1987). Evaluation of ulcerogenic effects in comparison with piroxicam: G. Palacios et al., ibid. 353. Clinical pharmacology: L. Martinez et al., ibid. 10, 729 (1988). Brief review of pharmacology: J. Esteve et al., Gen. Pharmacol. 19, 49-54 (1988).

Chemical structure

Properties

Crystals from acetone. mp 259-261°. LD50 orally in male, female mice, and male, female rats: 6192, 8841, 1434, 1994 mg/kg (Soler, 1986).

Therapeutic Category

Anti-inflammatory.

Keywords

Anti-inflammatory (Nonsteroidal); Thiazinecarboxamides

Status

This monograph has been retired and is no longer subject to revision or update.